Ocugen (OCGN) Hisse Özeti
Bir biyofarmasötik şirketi olan Ocugen, Inc. hastaların sağlığını iyileştiren yeni gen ve hücre tedavileri, biyolojik ve aşıların keşfedilmesi, geliştirilmesi ve ticarileştirilmesine odaklanmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 0/6 |
| Gelecekteki Büyüme | 5/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 3/6 |
| Temettüler | 0/6 |
OCGN Community Fair Values
Create NarrativeSee what 83 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Ocugen, Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$1.51 |
| 52 Haftanın En Yüksek Seviyesi | US$2.73 |
| 52 Haftanın En Düşük Seviyesi | US$0.91 |
| Beta | 2.18 |
| 1 Aylık Değişim | 17.97% |
| 3 Aylık Değişim | -14.69% |
| 1 Yıllık Değişim | 57.78% |
| 3 Yıllık Değişim | 169.64% |
| 5 Yıllık Değişim | -79.23% |
| Halka arzdan bu yana değişim | -47.02% |
Son Haberler & Güncellemeler
OCGN: Gene Therapy Pivotal Trials And 2027 Readouts Will Drive Repricing
Ocugen's analyst price target has shifted modestly, with one firm trimming its view from $12 to $11 while others recently raised their targets by $3 to $4. This reflects analysts' focus on the company's gene therapy pipeline, ongoing pivotal trials and upcoming clinical catalysts.OCGN: Retinal Gene Therapies Will Gain Momentum With Upcoming 2027 Readouts
Ocugen's analyst price target has edged down by $0.14 to $11.43 as analysts refresh their models around updated expectations for revenue growth, profitability, and long term P/E assumptions following recent gene therapy trial updates and upcoming catalysts across the retinal disease pipeline. Analyst Commentary Recent research updates show a mix of optimism around Ocugen's gene therapy pipeline and some caution on execution risk and timing, which is feeding into the modest reset in the average price target.Recent updates
OCGN: Gene Therapy Pivotal Trials And 2027 Readouts Will Drive Repricing
Ocugen's analyst price target has shifted modestly, with one firm trimming its view from $12 to $11 while others recently raised their targets by $3 to $4. This reflects analysts' focus on the company's gene therapy pipeline, ongoing pivotal trials and upcoming clinical catalysts.OCGN: Retinal Gene Therapies Will Gain Momentum With Upcoming 2027 Readouts
Ocugen's analyst price target has edged down by $0.14 to $11.43 as analysts refresh their models around updated expectations for revenue growth, profitability, and long term P/E assumptions following recent gene therapy trial updates and upcoming catalysts across the retinal disease pipeline. Analyst Commentary Recent research updates show a mix of optimism around Ocugen's gene therapy pipeline and some caution on execution risk and timing, which is feeding into the modest reset in the average price target.OCGN: Retinal Gene Therapy Pipeline Will Drive Future Upside Potential
Narrative Update on Ocugen Analyst price targets for Ocugen have moved higher, with several recent increases of $3 to $7 tied to positive preliminary data for OCU410, expectations around OCU400 in retinitis pigmentosa, and a growing view of the company as an emerging player in gene therapy for blinding ocular disorders. Analyst Commentary Recent research coverage on Ocugen centers on its gene therapy pipeline and the implications for valuation if key clinical and regulatory milestones are met.OCGN: Late Stage Retinal Gene Therapies Will Drive Future Upside Potential
Ocugen's analyst price targets have moved higher by several dollars, with analysts pointing to Ocugen's Phase 3 OCU400 program, early OCU410 data and a perceived opportunity in retinal disease markets as key reasons for the updated views. Analyst Commentary Recent research coverage on Ocugen has leaned constructive, with several firms updating their models and price targets after new clinical data and program milestones.OCGN: Retinal Gene Therapy Milestones Will Drive Future Upside Potential
Ocugen's updated fair value estimate has shifted to $11.57 from $10.36 as analysts factor in a series of higher price targets on the stock, supported by recent positive clinical data and new coverage that highlights its gene therapy pipeline in retinal diseases. Analyst Commentary Recent research on Ocugen is clustered around its gene therapy portfolio in retinal diseases, with several firms updating models and targets after new data readouts and coverage initiations.OCGN: Late Stage Gene Therapy Progress Will Drive Future Upside Potential
Ocugen's analyst price target has moved higher toward $22, reflecting updated fair value estimates of about $10.36 per share and analyst focus on recent OCU410 Phase 2 data and OCU400's Phase 3 progress in blinding ocular disorders. Analyst Commentary Recent research on Ocugen centers on how the new OCU410 Phase 2 readout and the OCU400 Phase 3 program could influence valuation, risk, and execution over the next few years.Ocugen: Downgrading After OCU410 Data Release
Summary Ocugen (OCGN) is downgraded from 'Buy' to 'Hold' due to concerns over OCU410's dose response in geographic atrophy. Preliminary phase 2 ArMaDa data showed a 46% reduction in lesion growth, but lacked dose-dependent efficacy and had a small sample size. Key catalysts include final ArMaDa data [March 2026], OCU410ST interim [Q3 2026] and topline [Q2 2027], and OCU400 RP topline [Q1 2027]. Company's cash runway extends to Q4 2026 [potentially Q2 2027 with warrant exercise], but quarterly burn and multiple late-stage trial risks remain. Read the full article on Seeking AlphaOCGN: Trial Progress And CFO Appointment Will Support Future Upside Potential
Narrative update on Ocugen Analysts have made a modest adjustment to their Ocugen price target, keeping fair value around $9.00. Small tweaks to the discount rate and future P/E assumptions refine, rather than overhaul, their view on the stock.OCGN: Positive Trial Data And New CFO Appointment Will Drive Upside
Ocugen's updated analyst price target edges higher, with a new fair value estimate of $9.00 per share supported by slightly adjusted assumptions for the discount rate, long term revenue growth, profit margin, and future P/E multiple. This indicates analysts are fine tuning their models rather than making a major shift in view.OCGN: Positive Trial Data And Capital Raise Will Drive Future Upside
Narrative Update The analyst price target for Ocugen has been fine tuned by a few cents, with only marginal shifts in fair value, discount rate, revenue growth, profit margin, and future P/E assumptions as analysts adjust their models in line with recent industry wide recalibrations seen in other coverage. Analyst Commentary Recent Street research on other companies in the broader building products and housing related space shows a mix of optimism on long term demand and caution around nearer term volatility.OCGN: Pipeline Milestones Will Drive Upside As Execution Risks Moderate
Analysts have trimmed their fair value estimate for Ocugen to $9.00. They link this move to slightly lower assumed discount rates and modest tweaks to long term revenue growth, profit margin, and future P/E expectations.OCGN: Pipeline Milestones Will Support Upside Despite Competitive And Capital Allocation Risks
Analysts have modestly trimmed their price target on Ocugen to around $9.00 per share. This reflects slightly lower discount rate and valuation assumptions as they factor in sustained but more competitively pressured growth and margins.OCGN: Exclusive Licensing Deal Will Drive Upside Amid Industry Headwinds
Ocugen's analyst price target remains steady at $9.00, as analysts cite ongoing competitive pressures and a lack of expected demand rebound in the sector as key factors for maintaining their current valuation outlook. Analyst Commentary Analyst sentiment around Ocugen reflects a balance of cautious optimism and ongoing concerns, shaped by sector-wide trends and company-specific challenges.OCGN: Upbeat Licensing Agreement Is Expected To Drive Shareholder Value In Coming Years
Narrative Update: Ocugen Analyst Price Target Revision Analysts have raised their price target for Ocugen from $8.20 to $9.00, citing increased revenue growth expectations and improved profit margin forecasts. Analyst Commentary Following the recent revision in Ocugen's price target, analysts have provided additional insight into the factors influencing their perspectives.OCGN: Future Licensing Deals And Regulatory Milestones Will Drive Long-Term Opportunity
Ocugen's analyst price target remained steady at $8.20, as analysts see unchanged fair value amid stable growth projections and profitability outlooks, according to recent reviews. Analyst Commentary Recent Street research provides a mixed outlook for Ocugen, reflecting both positive momentum and ongoing challenges as analysts assess the company's valuation and prospects for future growth.Gene Therapy Trials And Regulatory Approvals Will Open New Frontiers
Ocugen's analyst price target was reaffirmed at $8.20, as analysts cite stable revenue growth and profit margin projections, with only minor changes to discount rate and future P/E assumptions supporting their steady outlook. Analyst Commentary Street research highlights a range of perspectives surrounding Ocugen’s outlook, as analysts weigh factors that could either support or limit future upside in the company’s valuation and execution.Gene Therapy Trials And Regulatory Approvals Will Open New Frontiers
Ocugen's analyst price target has been raised significantly from $6.48 to $8.20, reflecting growing optimism among analysts based on stronger projected revenue growth and improving profit margins. Analyst Commentary Recent price target revisions signal a shift in analysts' outlook on Ocugen, highlighting both enthusiasm and lingering concerns regarding the company’s path forward.
Gene Therapy Advances Will Unlock New Treatment Options
Advancing gene therapies for unmet needs may drive significant future revenue growth and market share if upcoming products secure approvals.Hissedar Getirileri
| OCGN | US Biotechs | US Pazar | |
|---|---|---|---|
| 7D | 0.7% | 4.1% | 1.6% |
| 1Y | 57.8% | 41.1% | 18.6% |
Getiri vs. Endüstri: OCGN geçen yıl % 41.1 oranında getiri sağlayan US Biotechs sektörünü aştı.
Getiri vs Piyasa: OCGN geçen yıl % 18.6 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı
| OCGN volatility | |
|---|---|
| OCGN Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
İstikrarlı Hisse Senedi Fiyatı: OCGN son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: OCGN 'nin haftalık oynaklığı ( 10% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2013 | 116 | Shankar Musunuri | www.ocugen.com |
Bir biyofarmasötik şirketi olan Ocugen, Inc. hastaların sağlığını iyileştiren yeni gen ve hücre tedavileri, biyolojik ve aşıların keşfedilmesi, geliştirilmesi ve ticarileştirilmesine odaklanmaktadır. Şirketin boru hattı ürünü, şu anda retinitis pigmentosa tedavisi için Faz 3 denemeleri ve leber konjenital amaurosis tedavisi için Faz 1/2 denemeleri altında olan, genetik olarak çeşitli kalıtsal retina hastalıklarında retina bütünlüğünü ve işlevini geri kazandıran yeni bir gen terapisi ürün adayı olan OCU400'ü içerir; kuru yaşa bağlı makula dejenerasyonu (AMD) tedavisi için faz 1/2 altında bir gen terapisi olan OCU410; ve Stargardt hastalığının tedavisi için faz 1/2 altında bir gen terapisi olan OCU410ST. Diyabetik maküler ödem, diyabetik retinopati ve yaşa bağlı maküler dejenerasyon tedavisi için yeni bir rekombinant füzyon proteini olan OCU200 ve yetişkinlerde diz kıkırdağı yaralanmalarının onarımı için otolog kondrosit türevi bir neokartilaj olan NeoCart'ın geliştirilmesinde yer almaktadır.
Ocugen, Inc. Temel Bilgiler Özeti
| OCGN temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$511.17m |
| Kazançlar(TTM) | -US$71.67m |
| Gelir(TTM) | US$4.47m |
OCGN aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| OCGN gelir tablosu (TTM) | |
|---|---|
| Gelir | US$4.47m |
| Gelir Maliyeti | US$41.48m |
| Brüt Kâr | -US$37.01m |
| Diğer Giderler | US$34.66m |
| Kazançlar | -US$71.67m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -0.21 |
| Brüt Marj | -828.91% |
| Net Kâr Marjı | -1,605.22% |
| Borç/Özkaynak Oranı | 502.9% |
OCGN uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/05 10:56 |
| Gün Sonu Hisse Fiyatı | 2026/07/02 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Ocugen, Inc. 8 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Whitney Ijem | Canaccord Genuity |
| Daniil Gataulin | Chardan Capital Markets, LLC |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |